Page 28 - CBAC Newsletter 2016

Reference List (Continued)

167. Wang HS, Brown BS, McKinnon D, Cohen IS. Molecular basis for differential sensitivity of KCNQ and I(Ks)
168. channels to the cognitive enhancer XE991. Mol Pharmacol. 57, 1218-1223, 2000.

169. MacVinish LJ, Guo Y, Dixon AK, Murrell-Lagnado RD, Cuthbert AW. Xe991 reveals differences in K(+)
channels regulating chloride secretion in murine airway and colonic epithelium. Mol Pharmacol.
170. 60, 753-760, 2001.

171. Jepps TA, Chadha PS, Davis AJ, Harhun MI, Cockerill GW, Olesen SP, Hansen RS, Greenwood IA.
Downregulation of Kv7.4 channel activity in primary and secondary hypertension. Circulation. 124,
172. 602-611, 2011.
173.
174. Mackie AR, Brueggemann LI, Henderson KK, Shiels AJ, Cribbs LL, Scrogin KE, Byron KL. Vascular KCNQ
potassium channels as novel targets for the control of mesenteric artery constriction by vasopressin,
175. based on studies in single cells, pressurized arteries, and in vivo measurements of mesenteric vascular
176. resistance. J Pharmacol Exp Ther. 325, 475-483, 2008.
177.
Ng FL, Davis AJ, Jepps TA, Harhun MI, Yeung SY, Wan A, Reddy M, Melville D, Nardi A, Khong TK,
178. Greenwood IA. Expression and function of the K+ channel KCNQ genes in human arteries.
179. Br J Pharmacol. 162, 42-53, 2011.
180.
181. Zhong XZ, Harhun MI, Olesen SP, Ohya S, Moffatt JD, Cole WC, Greenwood IA. Participation of KCNQ (Kv7)
182. potassium channels in myogenic control of cerebral arterial diameter. J Physiol. 588, 3277-3293, 2010.
183.
Joshi S, Balan P, Gurney AM. Pulmonary vasoconstrictor action of KCNQ potassium channel blockers.
184. Respir Res. 7, 31, 2006.

Zaczek R, Chorvat RJ, Saye JA, Pierdomenico ME, Maciag CM, Logue AR, Fisher BN, Rominger DH,
Earl RA. Two new potent neurotransmitter release enhancers, 10,10-bis(4-pyridinylmethyl)-9(10H)-
anthracenone and 10,10-bis(2-fluoro-4-pyridinylmethyl)-9(10H)-anthracenone: comparison to linopirdine.
J Pharmacol Exp Ther. 285, 724-730, 1998.

Aiken SP, Zaczek R, Brown BS. Pharmacology of the neurotransmitter release enhancer linopirdine
(DuP 996), and insights into its mechanism of action. Adv Pharmacol. 35, 349-384, 1996.

Yeung SY, Greenwood IA. Electrophysiological and functional effects of the KCNQ channel blocker XE991 on
murine portal vein smooth muscle cells. Br J Pharmacol. 146, 585-595, 2005.

Lamas JA, Selyanko AA, Brown DA. Effects of a cognition-enhancer, linopirdine (DuP 996), on M-type
potassium currents (IK(M)) and some other voltage- and ligand-gated membrane currents in rat
sympathetic neurons. Eur J Neurosci. 9, 605-616, 1997.

Ohya S, Sergeant GP, Greenwood IA, Horowitz B. Molecular variants of KCNQ channels expressed in murine
portal vein myocytes: a role in delayed rectifier current. Circ Res. 92, 1016-1023, 2003.

Hernandez CC, Zaika O, Tolstykh GP, Shapiro MS. Regulation of neural KCNQ channels: signalling pathways,
structural motifs and functional implications. J Physiol. 586, 1811-1821, 2008.

Pena F, Alavez-Perez N. Epileptiform activity induced by pharmacologic reduction of M-current in the
developing hippocampus in vitro. Epilepsia. 47, 47-54, 2006.

Gerlach U. Blockers of the slowly delayed rectifier potassium IKs channel: potential antiarrhythmic agents.
Curr Med Chem Cardiovasc Hematol Agents. 1, 243-252, 2003.

Sanguinetti MC, Jurkiewicz NK. Delayed rectifier outward K+ current is composed of two currents in guinea
pig atrial cells. Am J Physiol. 260, H393-399, 1991.

Yang IC, Scherz MW, Bahinski A, Bennett PB, Murray KT. Stereoselective interactions of the enantiomers of
chromanol 293B with human voltage-gated potassium channels. J Pharmacol Exp Ther. 294,
955-962, 2000.

Lerche C, Bruhova I, Lerche H, Steinmeyer K, Wei AD, Strutz-Seebohm N, Lang F, Busch AE, Zhorov, BS,
Seebohm G. Chromanol 293B binding in KCNQ1 (Kv7.1) channels involves electrostatic interactions with
a potassium ion in the selectivity filter. Mol Pharmacol. 71, 1503-1511, 2007.

24 | CBAC Center Heartbeat